CXCR2 and neoplasm: In keeping with the critical role of IL-8 in cancer stemness, a function-blocking antibody against its receptor, CXCR-1, or a small-molecule inhibitor of CXCR-1 and CXCR-2, repertaxin, could deplete CSCs and inhibit tumor aggressiveness in human breast cancer xenografts (5).